BR112022020324A2 - Derivados de diamina macrocíclica como inibidores de ent para o tratamento de cânceres e combinação dos mesmos com antagonistas de receptor de adenosina - Google Patents
Derivados de diamina macrocíclica como inibidores de ent para o tratamento de cânceres e combinação dos mesmos com antagonistas de receptor de adenosinaInfo
- Publication number
- BR112022020324A2 BR112022020324A2 BR112022020324A BR112022020324A BR112022020324A2 BR 112022020324 A2 BR112022020324 A2 BR 112022020324A2 BR 112022020324 A BR112022020324 A BR 112022020324A BR 112022020324 A BR112022020324 A BR 112022020324A BR 112022020324 A2 BR112022020324 A2 BR 112022020324A2
- Authority
- BR
- Brazil
- Prior art keywords
- macrocyclic
- treatment
- diamine derivatives
- adenosine receptor
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006629P | 2020-04-07 | 2020-04-07 | |
| PCT/EP2021/059096 WO2021204896A1 (en) | 2020-04-07 | 2021-04-07 | Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020324A2 true BR112022020324A2 (pt) | 2023-03-07 |
Family
ID=75441913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020324A BR112022020324A2 (pt) | 2020-04-07 | 2021-04-07 | Derivados de diamina macrocíclica como inibidores de ent para o tratamento de cânceres e combinação dos mesmos com antagonistas de receptor de adenosina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230203058A1 (https=) |
| EP (1) | EP4132933A1 (https=) |
| JP (1) | JP7784041B2 (https=) |
| KR (1) | KR20230007369A (https=) |
| CN (2) | CN116535365A (https=) |
| AR (1) | AR121777A1 (https=) |
| AU (1) | AU2021253634A1 (https=) |
| BR (1) | BR112022020324A2 (https=) |
| CA (1) | CA3179526A1 (https=) |
| CL (1) | CL2022002772A1 (https=) |
| IL (1) | IL297127A (https=) |
| MX (1) | MX2022012558A (https=) |
| PH (1) | PH12022552981A1 (https=) |
| TW (1) | TW202204365A (https=) |
| WO (1) | WO2021204896A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118076610A (zh) * | 2021-10-06 | 2024-05-24 | Iteos比利时公司 | 具有ent1抑制活性的大环化合物 |
| KR20240089211A (ko) * | 2021-10-06 | 2024-06-20 | 아이테오스 벨지움 에스에이 | Ent1 억제 활성을 갖는 마크로시클릭 화합물의 제조 방법 |
| US20260069604A1 (en) * | 2022-06-01 | 2026-03-12 | Duke University | Novel equilibrative nucleoside transporter inhibitors and methods of making and using same |
| CN115417766B (zh) * | 2022-08-31 | 2024-05-17 | 天津药明康德新药开发有限公司 | 一种3-羟基-4,5二甲氧基苯甲酸叔丁酯的合成方法 |
| CN115650936B (zh) * | 2022-10-26 | 2024-11-01 | 天津药明康德新药开发有限公司 | 一种(叔丁基(3)-1,4-二氮杂卓-1-丙基)氨基甲酸酯的制备方法 |
| TW202444377A (zh) * | 2023-03-22 | 2024-11-16 | 比利時商艾托斯比利時公司 | 包括ent1抑制劑之鹽、結晶形式及水合物與溶劑合物的硫酸氫複合物 |
| TW202523332A (zh) | 2023-11-14 | 2025-06-16 | 比利時商艾托斯比利時公司 | Ｅｎｔ１抑制劑與檢查點抑制劑組合 |
| WO2025126110A1 (en) | 2023-12-15 | 2025-06-19 | iTeos Belgium SA | Ent1 inhibitors in combination with bispecific antibodies |
| WO2025163520A1 (en) | 2024-01-30 | 2025-08-07 | iTeos Belgium SA | Ent1 inhibitors for use in the treatment of diseases with increased adenosine levels |
| WO2025202864A1 (en) | 2024-03-25 | 2025-10-02 | iTeos Belgium SA | Ent1 inhibitors in combination with oncolytic viruses and their use in the treatment of cancer |
| WO2026038162A1 (en) | 2024-08-15 | 2026-02-19 | iTeos Belgium SA | Pharmaceutical compositions of ent1 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1646390B1 (en) * | 2003-07-22 | 2008-10-08 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
| JO3126B1 (ar) * | 2007-11-14 | 2017-09-20 | Janssen Pharmaceutica Nv | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| US9291747B2 (en) | 2010-02-08 | 2016-03-22 | Essilor International (Compagnie Generale D'optique) | Optical article comprising an anti-reflecting coating having anti-fogging properties |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| MA39822A (fr) * | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MX380313B (es) * | 2016-02-04 | 2025-03-12 | Univ Johns Hopkins | Rapadocinas, inhibidores de transportador 1 de nucleósido equilibrador y usos de los mismos. |
| US10131670B2 (en) * | 2016-12-16 | 2018-11-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Bicyclic heteroaryl derivatives as CFTR potentiators |
| HUE064141T2 (hu) | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| TWI801372B (zh) | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
-
2021
- 2021-04-07 KR KR1020227038825A patent/KR20230007369A/ko active Pending
- 2021-04-07 AU AU2021253634A patent/AU2021253634A1/en active Pending
- 2021-04-07 BR BR112022020324A patent/BR112022020324A2/pt unknown
- 2021-04-07 MX MX2022012558A patent/MX2022012558A/es unknown
- 2021-04-07 CA CA3179526A patent/CA3179526A1/en active Pending
- 2021-04-07 JP JP2022561072A patent/JP7784041B2/ja active Active
- 2021-04-07 CN CN202310367239.1A patent/CN116535365A/zh active Pending
- 2021-04-07 IL IL297127A patent/IL297127A/en unknown
- 2021-04-07 PH PH1/2022/552981A patent/PH12022552981A1/en unknown
- 2021-04-07 WO PCT/EP2021/059096 patent/WO2021204896A1/en not_active Ceased
- 2021-04-07 EP EP21717829.2A patent/EP4132933A1/en active Pending
- 2021-04-07 AR ARP210100908A patent/AR121777A1/es unknown
- 2021-04-07 CN CN202180040635.2A patent/CN115768773A/zh active Pending
- 2021-04-07 TW TW110112556A patent/TW202204365A/zh unknown
- 2021-04-07 US US17/917,462 patent/US20230203058A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002772A patent/CL2022002772A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116535365A (zh) | 2023-08-04 |
| AU2021253634A1 (en) | 2022-11-03 |
| WO2021204896A1 (en) | 2021-10-14 |
| TW202204365A (zh) | 2022-02-01 |
| CN115768773A (zh) | 2023-03-07 |
| PH12022552981A1 (en) | 2024-02-26 |
| KR20230007369A (ko) | 2023-01-12 |
| EP4132933A1 (en) | 2023-02-15 |
| JP7784041B2 (ja) | 2025-12-11 |
| CA3179526A1 (en) | 2021-10-14 |
| IL297127A (en) | 2022-12-01 |
| AR121777A1 (es) | 2022-07-06 |
| CL2022002772A1 (es) | 2023-06-16 |
| JP2023521351A (ja) | 2023-05-24 |
| MX2022012558A (es) | 2023-02-22 |
| US20230203058A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020324A2 (pt) | Derivados de diamina macrocíclica como inibidores de ent para o tratamento de cânceres e combinação dos mesmos com antagonistas de receptor de adenosina | |
| CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
| MX2021007833A (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. | |
| CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
| CO2021017981A2 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer | |
| CY1119176T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| SA521420965B1 (ar) | A2a/a2b مشتقات بيرازين مدمجة في صورة مثبطات | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| AR119207A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| CR20140515A (es) | Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso | |
| CL2021001039A1 (es) | Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. | |
| CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
| NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| CO6491026A2 (es) | Compuestos de benzoxazapina como inhibidores de la pi3k y metodos de uso | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| DE602007005241D1 (de) | Purin-derivate als a2a-rezeptor-agonisten | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
| EA202192093A1 (ru) | Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b | |
| NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
| MX2019011743A (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres. |